Assessment of Efficacy, Safety and Dosing of Clevidipine in Pediatric Participants Undergoing Surgery (PIONEER)

Study Identifier:
MDCO-CLV-12-01
ClinicalTrials.gov Identifier:
NCT01938547
EudraCT Identifier:
N/A
EU CT ID:
N/A
Study Contact Information:
N/A
Terminated/Withdrawn

Trial Documents

Protocol
Available Languages: English
Download document(s)
Statistical Analysis Plan
Available Languages: English
Download document(s)
Clinical Study Report
Available Languages: English
Download document(s)
Plain Language Summary
Available Languages: English
Download document(s)

Study Details

Medical Condition
  • Hypertension
Study Drug
  • Drug: clevidipine
Date
Mar 2014 - Feb 2024
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: N/A - 17 Years
Requirements Information
Inclusion and Exclusion Criteria
Inclusion Criteria
  • Less than 18 years of age
  • Written informed consent obtained before initiation of any study-related procedures
  • The enrolling physician determines that the participant will likely require a 15% reduction in BP during the perioperative course
  • Intra-arterial line is available for blood pressure monitoring
  • Surgical procedure requiring a minimum of 1 hour of anesthesia, in which IV antihypertensive therapy to control BP for at least 30 minutes is anticipated
Exclusion Criteria
  • Administration of an IV or oral antihypertensive agent within 2 hours prior to study drug administration
  • Congenital heart disease described as single ventricle
  • Evidence of liver failure, severe liver disease, pulmonary disease (e.g. uncontrolled asthma), hyperlipidemia, lipoid nephrosis, lipid dysfunction or acute pancreatitis
  • Allergy to soya bean oil or egg lecithin
  • Known to be intolerant to calcium channel blockers
  • Hemophilia or blood coagulation disorders
  • Any serious medical condition which, in the opinion of the investigator, is likely to interfere with study procedures
  • Clinically significant abnormal physical findings at the screening evaluation
  • Any serious surgical or medical condition which, in the opinion of the investigator, is likely to interfere with study procedures or with the pharmacokinetics or pharmacodynamics of the study drug
  • Participant is terminally ill (death likely to occur within 48 hours)
  • Use of Methylphenidate, calcium channel blockers, Aripiprazole and other atypical anti- psychotics and antihypertensives used for BP control within 2 hours prior to study drug initiation
  • Positive serum or urine pregnancy test for any female of child bearing potential
  • Participation in other clinical research studies involving the evaluation of other investigational drugs or devices within 30 days of enrollment
  • Participants who, for any reason, are deemed by the Investigator to be inappropriate for this study
  • Participant is a relative of the Investigator or his/her deputy, research assistant, pharmacist, study coordinator, other staff directly involved in the conduct of the study
Healthy Volunteers
No

Protocol Summary

Evaluate the efficacy, safety, and dosing of clevidipine as an intravenous (IV) infusion for blood pressure (BP) management in paediatric participants in the perioperative setting.

Study Locations

Location
Status
Location
Stanford Medical Center
Stanford, California, United States, 94305
Status
N/A
Location
Nationwide Children's Hospital
Columbus, Ohio, United States, 43205
Status
N/A